DermTech Joins PeDRA Corporate Council, Supporting Efforts to Address Pediatric Skin Diseases
July 06 2022 - 04:30PM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a
leader in precision dermatology enabled by a non-invasive skin
genomics platform, announced today its membership in the Corporate
Council of the Pediatric Dermatology Research Alliance (PeDRA).
PeDRA is a nonprofit research network with the mission to create,
inspire and sustain research to prevent, treat and cure childhood
skin disease by bringing together pediatric dermatologists for
organized studies and collaborative initiatives. With more than 600
members, PeDRA is accelerating research and advancing development
of new treatments for children living with dermatologic
diseases.
As a member of the PeDRA Corporate Council, DermTech will
contribute to the development and expansion of PeDRA’s research
infrastructure and serve as a valuable partner to PeDRA members.
This aligns with the capabilities of DermTech Stratum™, a
translational medicine service offering that enables non-invasive
approaches to precision and personalized dermatology using
biomarker platform technology and subsequent analysis.
"We are proud to join the PeDRA Corporate Council to help
progress research and treatment options for children impacted by
life-altering skin diseases,” said Michael Howell, Ph.D., chief
scientific officer at DermTech. “By leveraging precision
dermatology, we are providing a non-invasive way to improve how a
variety of skin diseases are diagnosed and treated. We look forward
to working with the PeDRA team and other like-minded Corporate
Council members to advance this mission.”
DermTech’s membership comes ahead of the 2022 PeDRA Corporate
Council Roundtable, taking place on July 8, 2022 in Indianapolis,
Ind. Titled “PeDRA’s Role in Consensus Guidelines and Best Practice
Recommendations,” the event will focus on the development of
guidelines and recommendations in pediatric dermatology. DermTech
will also attend the 10th PeDRA Annual Conference, taking place
from November 3 – 5, 2022 in Bethesda, Md., which is expected to
bring more than 350 scientists, industry partners, patients and
advocates together.
For additional information about DermTech Stratum, visit
https://dermtechstratum.com/.
About DermTech:
DermTech is a leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by its non-invasive skin genomics platform. DermTech’s mission is
to improve the lives of millions by providing non-invasive
precision dermatology solutions that enable individualized care.
DermTech provides genomic analysis of skin samples collected
non-invasively using its Smart Stickers™. DermTech markets and
develops products that facilitate the early detection of skin
cancers and is developing products that assess inflammatory
diseases and customize drug treatments. For additional information,
please visit DermTech.
Forward-Looking Statements:
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations with respect to: the performance, patient
benefits, benefits to research partners and collaborators,
cost-effectiveness, commercialization and adoption of DermTech’s
products and services and the market opportunity therefor, and
DermTech’s ability to expand its product and service offerings.
These forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from the expected results. Most of these factors are
outside of the control of DermTech and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: (1) the outcome of any legal proceedings that may be
instituted against DermTech; (2) DermTech’s ability to obtain
additional funding to develop and market its products and services;
(3) the existence of favorable or unfavorable clinical guidelines
for DermTech’s tests; (4) the reimbursement of DermTech’s tests by
Medicare and private payors; (5) the ability of patients or
healthcare providers to obtain coverage of or sufficient
reimbursement for DermTech’s products; (6) DermTech’s ability to
grow, manage growth and retain its key employees; (7) changes in
applicable laws or regulations; (8) the market adoption and demand
for DermTech’s products and services together with the possibility
that DermTech may be adversely affected by other economic,
business, and/or competitive factors; and (9) other risks and
uncertainties included in (x) the “Risk Factors” section of the
most recent Annual Report on Form 10-K filed by DermTech with the
Securities and Exchange Commission (the “SEC”), and (y) other
documents filed or to be filed by DermTech with the SEC. DermTech
cautions that the foregoing list of factors is not exclusive. You
should not place undue reliance upon any forward-looking
statements, which speak only as of the date made. DermTech does not
undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220706005171/en/
Steve Kunszabo (858) 291-1647 steve.kunszabo@dermtech.com
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Feb 2024 to Mar 2024
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Mar 2023 to Mar 2024